Clinical Trial Update: A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating BioTTT001, a recombinant human nsIL12 oncolytic adenovirus injection, in combination with neoadjuvant therapy for locally advanced brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BioTTT001

Snippet

Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Conditions: Locally Advanced Breast Cancer (LABC) | Phase 1 | Status: WITHDRAWN